Nirmatrelvir plus ritonavir for treating COVID-19

Contains redacted PART 1 slides

Part review of TA878

Technology appraisal committee C

Chair: Stephen O'Brien

Evidence assessment group: School of Health and Related Research (ScHARR), Sheffield

Technical team: Anna Brett, Anuja Chatterjee, Adam Brooke, Ross Dent

Company: Pfizer

Recap and Decision problem

NICE National Institute for Health and Care Excellence

Recommendation for nirmatrelvir plus ritonavir

Nirmatrelvir plus ritonavir is recommended as an option for treating COVID-19 in adults, only if they:

- do not need supplemental oxygen for COVID-19 and
- have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care. (McInnes report)

Aim of review

Is nirmatrelvir plus ritonavir clinically and cost-effective in broader population than McInnes report?

DHSC Antiviral and Therapeutics Task force commissioned a report by John Edmund's (Edmund's report) to assess whether there are any groups that have a risk that is at least as high as McInnes groups (published 29 March 2023) McInnes criteria for highest risk

Age over 70, diabetes and obesity have same risk as lowest risk groups in McInnes report

Company submitted additional evidence for nirmatrelvir plus ritonavir after final draft guidance issued to support expansion of the high-risk group definition Company submitted evidence and request committee consider broadening recommendation for all age over 60+ or 18-59 with 1 risk factor

Key issues for discussion

Expansion of high-risk group definition

Issue	ICER impact	Population size impact and decision risk
Is nirmatrelvir plus ritonavir clinically and cost effective for people who are 70 years and over?	Moderate	High
Is nirmatrelvir plus ritonavir clinically and cost effective for any other groups?	Large	Very high

Final guidance and model recap

Unlike other risk factors age can be adjusted within the model framework

Final guidance section 3.6:

- Committee noted evidence at a subgroup level is limited and too uncertain to parameterise the model, additional functionality and input assumptions maybe needed
- ✓ Committee specified additional evidence needed to model age over 70 years

Model recap:

- The AG model does not include functionality to model individual subgroups split by the risk factors
- Unlike specific risk factors like diabetes or obesity, age can be adjusted by changing the starting age in the mild COVID-19 setting
 - This affects cost-effectiveness because average age in model is 55, so increasing eligibility to 70+ would increase average age → shorter time to accrue QALYs from avoiding mortality

Additional evidence provided by company include:

- Treatment specific (nirmatrelvir plus ritonavir) hospitalisation and mortality rates split by age
- Relative treatment effect of nirmatrelvir plus ritonavir (versus untreated/ standard care) in terms of hospitalisation and mortality rates split by age
 - Hospitalisation or death relative risk
 - All-cause mortality relative risk at 28 days

McInnes definition and Edmunds report

McInnes: People more likely to develop severe COVID-19

Some people have a health condition that may increase their risk of getting seriously ill from COVID-19, such as:

- Down's syndrome
- certain types of cancer including leukaemia
- certain conditions affecting the blood, such as sickle cell disease
- people who have had a stem cell transplant
- kidney disease
- liver disease
- people who have had an organ transplant
- conditions affecting the immune system, such as HIV or AIDS, inflammatory conditions or immunodeficiency
- conditions affecting the brain or nerves (multiple sclerosis, motor neurone disease, Huntington's disease or myasthenia gravis).



OpenSAFELY (Delta wave) (May – Dec 2021) N = 18.7 million

Hippisley-Cox 2022 (Omicron wave) Dec 2021-March 2022 N = 1.3 million

Edmunds 2023 report using 3 UK/England cohort studies and recommendations from DHSC: Age 70 years and above, diabetes and obesity have same risk as lowest risk group in McInnes

Evidence within Edmunds paper

NICE National Institute for Health and Care Excellence

Death rate per 1000 person years across waves (All waves)



Death rate during the Delta wave from OpenSAFELY

NICE



OpenSAFELY

(Delta wave)

Adjusted rate associated with hospitalisation or death



Adjusted rate associated with hospitalisation or death



Agrawal 2022 (Omicron wave) (Dec 2021-Feb 2022) N = 30 million



Adjusted HR of COVID-19

death in women (Q-CC	DVID4)	Blood cancer Marrow transplant Respiratory cancer Radiotherapy in last 6/12 Solid organ transplant Immunosuppressants	* * * *	1.30 (1.03, 1.63) 5.64 (1.04, 30.72) 2.06 (1.52, 2.80) 2.96 (2.00, 4.40) 5.83 (2.49, 13.63) 1.90 (1.09, 3.31)
Hippisley-Cox 2022 (Omicron wave) Dec 2021-March 2022 N = 1.3 million		Leukotriene/LABA Oral steroids COPD Pulm hypertension/fibrosis Coronary heart disease Stroke Atrial fibrillation Congestive cardiac failure Thromboembolism PVD		1.27 (1.09, 1.48) 1.57 (1.33, 1.86) 1.71 (1.46, 1.99) 1.67 (1.12, 2.50) 1.14 (1.01, 1.28) 1.11 (0.97, 1.26) 1.09 (0.96, 1.24) 1.63 (1.41, 1.88) 1.42 (1.23, 1.63) 1.51 (1.23, 1.86)
No learning disability	1.00	Dementia	•	1.27 (1.14, 1.42)
Learning disability'	1.06 (0.77, 1.45)	Parkinson's disease	+	1.69 (1.23, 2.33)
	10.10 (1.42, 72.11)	Epilepsy Rare neuro conditions	-	1.41 (1.07, 1.87)
No kidney failure	1.00	Osteoporotic fracture	•	1.12 (1.01, 1.26)
CKD stage 3	1.20 (1.08, 1.34)	Rheumatoid arthritis or SLE	•	1.18 (1.01, 1.37)
CKD stage 4	1.01 (1.20, 2.07)	Cirrhosis of the liver	-	1.75 (1.17, 2.62)
CKD stage 5(dialysis)	1.98 (0.74, 5.33)	Schizophrenia or bipolar		0.91 (0.64, 1.29)
CKD stage 5 (transplant)	6.64 (3.43, 12.83)	Sickle cell or HIV/AIDS/SCID		2 53 (1 42 4 50)
		Type1 diabetes		3.79 (2.02, 7.11)
No chemotherapy	1.00	Type2 diabetes	•	1.45 (1.29, 1.62)
Chemotherapy grade A	3.68 (2.72, 5.54) 7.28 (5.41, 9.79)			
Chemotherapy grade C	9.26 (3.09, 27,73)	12.2	5512481622	
		. 12.2	0.012401032	

Adjusted hazard ratios for age and risk of COVID-19 deaths/hospital admissions derived from the living risk prediction algorithm QCOVID



 QCOVID study controlled for other covariates when calculating hazard ratios for age related risk; therefore, the data represents the impact of age on mortality and hospitalisation alone

Updated clinical evidence

NICE National Institute for Health and Care Excellence

CONFIDENTIAL

Company requested subgroup data from PANORAMIC

ompany comments						
Preferred high-risk definition: includes all aged over 60 and between 18-59 year with at least one pre-existing health condition		70 years+*	65 years+*	60 years+* EPIC-HR full trial	PANORAMIC Full trial 50 years+*	
 Rationale for wider cohort: QCOVID algorithm and ISARIC report shows age is an independent risk factor and age 50+ is at least as comparable to the McInnes defined population JCVI's routinely used criteria is to recommended access to the COVID-19 vaccine for ages 50 years and above - Similar criteria should also apply for treatment of COVID-19 Data has been provided from PANORAMIC and the nirmatrelvir plus ritonavir's EPIC- HR trial. Data from EPIC-SR could not be provided due to low event numbers. 	Mean age non- hospital setting				56.6	
	Baseline hospitalisation rate from PANORAMIC (Placebo arm)				0.77%	
	Relative risk of death from any cause through day 28 (95% CI)				0.15 (0.001-0.63)	
	Relative risk of hospitalisation or death (95% CI)				0.14 (0.07-0.27)	

Table[•] PANORAMIC and EPIC-HR trial data

denotes: Also includes 18–59 years with ≥ 1 high risk condition

CI, Confidence interval; JCVI, Joint Committee on Vaccination and Immunisation NICE

Company comments

AG comments on PANORAMIC and EPIC HR data

AG comments:

- Results presented by Pfizer which included younger age groups were deemed inappropriate. Individual age groups should have been modelled to generate consistent and unbiased outcomes (for example 65-69 instead of 65 years and below). (See Table 1 in AG critique)
- To model 70+, AG's preference was to use the mean age groups for community and hospital settings and the hospitalisation and 28 day mortality rates for the standard care arm from PANORAMIC
- For relative treatment effect of nirmatrelvir/ritonavir compared with standard care, two different analysis were done. One used COVID-NMA outcomes and the second used publicly available data from EPIC-SR. For the EPIC-SR scenario, no mortality benefit was assumed for nirmatrelvir/ritonavir.

NICE tech team comments:

EPIC-SR is a relevant trial because it is reflective of a vaccinated population. As of March 2023, 90% of
people between 70-74 were vaccinated with the COVID-19 third/booster dose in England. The relative
treatment effect of nirmatrelvir plus ritonavir compared with standard care from EPIC-SR is therefore relevant
for decision making. As stated in final guidance, the preliminary outcomes showed non-significant reduction in
hospitalisation rates in the vaccinated high-risk subgroup.

Costeffectiveness results

NICE National Institute for Health and Care Excellence CONFIDENTIAL

FG base case and scenarios considered by AG

	High-risk population (as in final guidance (FG))	70 years and over – Scenario 1	70 years and over – Scenario 2	High-risk population (as in FG) plus 70 years and over - Scenario 3	The Pfizer analysis deemed by the EAG to be the most representative of NICE's request
Mean age of hospitalised patients (years)	55.0			70.0	
Mean age of non-hospitalised patients (years)	55.0			65.0	
Baseline hospitalisation rate (with standard care)	2.82%			2.82%	
Baseline 28-day mortality rate (with standard care)	0.68%			0.68%	
Nirmatrelvir/ritonavir hospitalisation or death relative risk	Median: 0.13 95% CI: 0.07-0.27 Mean: 0.14	Median: 0.13 95% CI: 0.07-0.27 Mean: 0.14	EPIC-SR: Median: 0.43 95% CI: 0.11-1.64 Mean: 0.55	Median: 0.13 95% CI: 0.07-0.27 Mean: 0.14	
Nirmatrelvir/ritonavir all-cause day 28 mortality relative risk	Median: 0.04 95% CI: 0.00-0.63 Mean: 0.15	Median: 0.04 95% CI: 0.00-0.63 Mean: 0.15	Assumption: 1	Median: 0.04 95% CI: 0.00-0.63 Mean: 0.15	

Please see AG critique for further details and input parameter assumptions; CI, Confidence interval

AG results assuming mean efficacy

Table: Deterministic incremental results for scenarios 1 to 3

Technology	Total costs (£)	Total QALYs	ICER versus SoC (£/QALY)	NMB (£20,000 / QALY)	NMB (£30,000 / QALY)				
Scenario 1 (baseline rates from PANORAMIC + efficacy data from COVID-NMA)									
SoC	711	6.51	-	-	-				
Nirmatrelvir/ritonavir	1761	6.55	26,381	-254	144				
Scenario 2 (baseline rates from PANC	DRAMIC + effica	acy data from E	PIC-SR with assum	ptions)					
SoC	711	6.51	-	-	-				
Nirmatrelvir/ritonavir	1811	6.53	61,454	-742	-563				
Scenario 3 (baseline rates from previous high-risk analyses, efficacy data from COVID-NMA and starting ages of 70									
and 65 for hospitalised and non-hospitalised patients)									
SoC	1053	9.97	-	-	-				
Nirmatrelvir/ritonavir	1805	10.10	5516	1975	3339				

ICERs ranging from below £20000 per QALY gained to above £50,000 per QALY gained.

NICE

AG results assuming low efficacy

Table: Deterministic incremental results for scenarios 1 to 3

NICE

Technology	Total costs (£)	Total QALYs	ICER versus SoC (£/QALY)	NMB (£20,000 / QALY)	NMB (£30,000 / QALY)				
Scenario 1 (baseline rates from PANORAMIC + efficacy data from COVID-NMA)									
SoC	711	6.51	-	-	-				
Nirmatrelvir/ritonavir	1766	6.54	33,615	-427	-113				
Scenario 2 (baseline rates from PANC	DRAMIC + effica	acy data from E	PIC-SR with assum	nptions)					
SoC	711	6.51	-	-	-				
Nirmatrelvir/ritonavir	1950	6.51	Dominated	-1239	-1239				
Scenario 3 (baseline rates from previ	ous high-risk an	alyses, efficacy	data from COVID-	NMA and startin	ng ages of 70				
and 65 for hospitalised and non-hospitalised patients)									
SoC	1053	9.97	-	-	-				
Nirmatrelvir/ritonavir	1817	10.07	7827	1188	2164				

ICERs ranging from below £20000 per QALY gained to dominated (no QALY gains in scenario 2).

ICER, Incremental cost effectiveness ratio; QALY, Quality adjusted life years; NMB, Net monetary benefit; SoC, Standard care

Back-up slides



OpenSAFELY adapted figure from Edmunds report (1/2)

Wave • 1 • 2 • 3



Figure: OpenSAFELY Hazard ratio of death by demographic and socioeconomic variables



The 95% CI on the hazard for rheumatoid arthritis, lupus and psoriasis In the third wave is highlighted with a blue shaded bar

Figure: OpenSAFELY Hazard ratio of death by clinical conditions

Wave • 1 • 2 • 3

OpenSAFELY adapted figure from Edmunds report (2/2)

Figure: Sex- and age-standardised COVID-19-related death rates (IR) and 95% confidence intervals per 1,000 person-years in OpenSAFELY in the three pandemic waves. Models were standardised for age and sex using the European standard population except for the death rates by age group (not standardised) and death rates by sex (standardised by age).

The 95% CI on the hazard for rheumatoid arthritis, lupus and psoriasis

NICE

In the third wave is highlighted with a – blue shaded bar





Agrawal adapted figure from Edmunds report



The 95% CI for the risk ratio associated with rheumatoid arthritis or SLE

Figure: Adjusted rate ratios (95% confidence intervals) for specific clinical risk factors associated with COVID-19 hospitalisation or death, among individuals who received booster doses MRNA-1273 or BNT162b2

Hippisley-Cox adapted figure from Edmunds **report (1/2)**

(a)

Figure: Adjusted hazard ratio of deaths by clinical risk groups for males (a) and females (b). Adjustment for all variables including age and BMI.

NICE

	Adj HR 95% CI
Deprivation (5 unit increase)	1.18 (1.09, 1.27)
White	1.00
Indian	0.60 (0.48, 0.00)
Dekisteni	0.09 (0.46, 0.99)
Pakistani	0.77 (0.50, 1.19)
Other Asian	1.14 (0.00, 1.97)
Caribbean	0.72 (0.44, 1.20)
Black african	0.59 (0.35, 0.80)
Chinese	0.93 (0.35, 0.96)
Other ethnic group	0.85 (0.60, 1.20)
	0.00 (0.00, 1.20)
No learning disability	1.00
wown's syndrome	4.86 (1.21, 19.54
No kidney failure	1.00
CKD stage 3	1.14 (1.02, 1.27)
CKD stage 4	1.66 (1.30, 2.12)
CKD stage 5	1.63 (1.17, 2.26)
CKD stage 5(dialysis)	1.04 (0.46, 2.34)
CKD stage 5 (transplant)	6.14 (3.66, 10.30
No chemotherapy	1.00
Chemotherapy grade A	 3.80 (2.76, 5.22)
Chemotherapy grade B	 5.83 (4.57, 7.44)
Chemotherapy grade C	10.91 (5.37, 22.1
No COVID vaccine	1.00
1 dose -	0.58 (0.43, 0.79)
2 doses +	0.50 (0.42, 0.60)
3 doses +	0.19 (0.16, 0.22)
4+ doses	0.08 (0.06, 0.12)
prior SARS-CoV-2 -	0.51 (0.40, 0.64)
Blood cancer	1.57 (1.31, 1.89)
Marrow transplant	0.84 (0.11, 6.67)
Respiratory cancer	1.71 (1.30, 2.25)
Radiotherapy in last 6/12	 3.06 (2.26, 4.13)
Solid organ transplant	2.36 (0.86, 6.50)
Immunosuppressants	1.65 (1.00, 2.74)
Leukotriene/LABA	0.94 (0.80, 1.11)
Oral steroids	1.89 (1.59, 2.24)
COPD	1.48 (1.28, 1.71)
Pulm hypertension/fibrosis	0.82 (0.45, 1.50)
Coronary heart disease	1 17 (1 05 1 29)
Stroke	1 21 (1 08, 1 36)
Atrial fibrillation	1 18 (1 06 1 32)
Congretive cardiac failure	1.41 (1.24, 1.60)
Thromboombolism	1.41 (1.24, 1.00)
PVD +	1.07 (0.90, 1.28)
Demontia	1 60 /1 45 4 941
Deriver and Derive	1.02 (1.45, 1.81)
Fallengu	2.22 (1.80, 2.73)
Epilepsy	1.28 (0.99, 1.65)
kare neuro conditions	1.25 (0.74, 2.12)
Osteoporotic fracture	1.12 (0.98, 1.29)
Rheumatoid arthritis or SLE	1.24 (1.04, 1.48)
Cirrhosis of the liver	- 2.52 (1.83, 3.45)
Schizophrenia or bipolar	1.55 (1.14, 2.11)
Inflammatory bowel disease	1.10 (0.78, 1.57)
Sickle cell or HIV/AIDS/SCID	1.51 (0.83, 2.76)
Type1 diabetes	 3.40 (1.94, 5.95)
Type2 diabetes	1.44 (1.30, 1.60)

Deprivation (5 unit increase) 1.18 (1.08, 1.28) White 1.00 0.66 (0.40, 1.07) Indian 1.16 (0.74, 1.84) Pakistani Bangladeshi 1.74 (0.96, 3.14) Other Asian 1.55 (0.98, 2.44) Caribbean 0.71 (0.50, 1.02) Black african 1.37 (0.91, 2.08) Chinese 0.80 (0.26, 2.41) Other ethnic group 0.39 (0.23, 0.69) 1.00 No learning disability s prosinition of the second se 1.06 (0.77, 1.45) 10.16 (1.42, 72.77) 1.00 No kidney failure 1.20 (1.08, 1.34) CKD stage 3 CKD stage 4 1.61 (1.26, 2.07) CKD stage 5 2.09 (1.44, 3.04) CKD stage 5(dialysis) 1.98 (0.74, 5.33) CKD stage 5 (transplant) 6.64 (3.43, 12.83) No chemotherapy 1.00 3.88 (2.72, 5.54) Chemotherapy grade A Chemotherapy grade B 7.28 (5.41, 9.79) Chemotherapy grade C 9.26 (3.09, 27.73) No COVID vaccine 1.00 0.64 (0.47, 0.87) 1 dose 0.49 (0.41, 0.59) 2 doses 0.20 (0.17, 0.24) 3 doses 0.14 (0.10, 0.20) 4+ doses prior SARS-CoV-2 0.55 (0.45, 0.67) 1.30 (1.03, 1.63) Blood cancer Marrow transplant 5.64 (1.04, 30.72) Respiratory cancer 2.06 (1.52, 2.80) Radiotherapy in last 6/12 2.96 (2.00, 4.40) Solid organ transplant 5.83 (2.49, 13.63) Immunosuppressants 1.90 (1.09, 3.31) 1.27 (1.09, 1.48) Leukotriene/LABA Oral steroids 1.57 (1.33, 1.86) COPD 1.71 (1.46, 1.99) Pulm hypertension/fibrosis 1.67 (1.12, 2.50) Coronary heart disease 1.14 (1.01, 1.28) 1.11 (0.97, 1.26) Stroke Atrial fibrillation 1.09 (0.96, 1.24) Congestive cardiac failure 1.63 (1.41, 1.88) Thromboembolism 1.42 (1.23, 1.63) PVD 1.51 (1.23, 1.86) Dementia 1.27 (1.14, 1.42) Parkinson's disease 1.69 (1.23, 2.33) Epilepsy 1.41 (1.07, 1.87) Rare neuro conditions 2.30 (1.47, 3.59) 1.12 (1.01, 1.26) Osteoporotic fracture Rheumatoid arthritis or SLE 1.18 (1.01, 1.37) 1.75 (1.17, 2.62) Cirrhosis of the liver Schizophrenia or bipolar 0.91 (0.64, 1.29) Inflammatory bowel disease 1.30 (0.94, 1.80) Sickle cell or HIV/AIDS/SCID 2.53 (1.42, 4.50) Type1 diabetes 3.79 (2.02, 7.11) Type2 diabetes 1.45 (1.29, 1.62) .12.25.5 1 2 4 8 16 32

26

Adj HR 95% CI

Hippisley-Cox adapted figure from Edmunds **report (2/2)**

Figure: Adjusted hazard ratio of hospitalisation by clinical risk groups for males (a) and females (b). Adjustment for all variables including age and BMI.

NICE

		Adj HR 95% CI
a)	Deprivation (5 unit increase)	1.37 (1.31, 1.42)
~,	White	1.00
	Indian	0.90 (0.78, 1.05)
	Pakistani	1 47 (1 24 1 74)
	Banaladeshi	1.26 (1.02 1.55)
	Other Asian	1.20 (1.02, 1.33)
	Caribbean	0.90 (0.76, 1.07)
	Black african	1 12 (0.06 1 21)
	Chippen	0.91 (0.54, 1.21)
	Other ethnic group	1.05 (0.92, 1.21)
	No learning disability	1.00
	Learning disability'	173 (153 196)
	Down's syndrome	6.15 (3.95, 9.57)
	No kidney failure	1.00
	CKD stage 3	1.16 (1.07, 1.25)
	CKD stage 4	1.97 (1.65, 2.35)
	CKD stage 5	2.51 (2.10, 3.01)
	CKD stage 5(dialysis)	1.56 (1.05, 2.31)
	CKD stage 5 (transplant)	 7.90 (6.59, 9.48)
	No chemotherapy	1.00
	Chemotherapy grade A	2.41 (1.90, 3.06)
	Chemotherapy grade B	 3.90 (3.30, 4.61) 4.47 (2.45, 8.15)
	No COVID vaccine	1.00
	1 dose	0.66 (0.58, 0.75)
	2 doses	0 40 (0 37 0 43)
	3 doses	0.24 (0.23, 0.26)
	4+ doses	0.27 (0.23, 0.31)
	prior SARS-CoV-2	0.61 (0.56, 0.68)
		0.07 (0.00, 0.00)
	Blood cancer	1.97 (1.76, 2.21)
	Marrow transplant	2.90 (1.03, 8.14)
	Respiratory cancer	1.39 (1.11, 1.74)
	Radiotherapy in last 6/12	2.12 (1.67, 2.68)
	Solid organ transplant	 3.11 (2.20, 4.41)
	Immunosuppressants +	1.79 (1.48, 2.16)
	Leukotriene/LABA	1.36 (1.24, 1.49)
	Oral steroids	2.15 (1.96, 2.37)
	COPD	1.32 (1.20, 1.46)
	Pulm hypertension/fibrosis	1.11 (0.75, 1.63)
	Coronary heart disease	1.15 (1.07, 1.23)
	Stroke	1.42 (1.31, 1.53)
	Atrial fibrillation	1.11 (1.03, 1.20)
	Congestive cardiac failure	1.36 (1.24, 1.50)
	Thromboembolism	1.44 (1.31, 1.57)
	PVD •	1.11 (0.98, 1.25)
	Dementia 🔶	1.27 (1.16, 1.39)
	Parkinson's disease	1.47 (1.22, 1.78)
	Epilepsy	1.87 (1.65, 2.11)
	Rare neuro conditions	 4.01 (3.37, 4.78)
	Osteoporotic fracture	1.13 (1.03, 1.24)
	Rheumatoid arthritis or SLE	1.41 (1.28, 1.56)
	Cirrhosis of the liver	2.18 (1.80, 2.63)
	Schizophrenia or bipolar	1.90 (1.64, 2.19)
	Inflammatory bowel disease	2.55 (2.25, 2.88)
	Sickle cell or HIV/AIDS/SCID	1.65 (1.29, 2.12)
	Type1 diabetes	3 34 (2 76 4 02)
	Type? diabetes	1 44 (1 35 1 53)
	The danetes	1.44 (1.00, 1.00)
		4 9 16 22
	.12 .25 .5 1 2	4 8 16 32

		Adj HR 95% CI
Deprivation (5 unit increase)	•	1.17 (1.13, 1.21)
14.0.1		4.00
white	1	1.00
Indian	†	1.00 (0.88, 1.15)
Pakistani	1	1.69 (1.45, 1.96)
Bangladeshi	1	1.64 (1.40, 1.92)
Other Asian		1.21 (1.05, 1.40)
Caribbean	†	1.06 (0.91, 1.23)
Black african	•	1.27 (1.13, 1.42)
Chinese -	-111	0.64 (0.48, 0.86)
Other ethnic group	t	1.04 (0.95, 1.15)
No learning disability	+	1.00
Learning disability bown's syndrome	1	1.54 (1.36, 1.75) 5.26 (3.31, 8.38)
No kidney failure		1.00
CKD stage 2	T	1.00
CKD stage 5		1.24 (1.10, 1.34)
CKD stage 4	T	1.55 (1.20, 1.00)
CKD stage 5		3.89 (3.21, 4.72)
CKD stage 5(dialysis)		2.36 (1.57, 3.53)
CKD stage 5 (transplant)	•	8.42 (6.91, 10.26
No chemotherapy	•	1.00
Chemotherapy grade A		3.33 (2.70, 4.10)
Chemotherapy grade B	+	4.76 (4.01, 5.65)
Chemotherapy grade C		3.69 (1.95, 6.98)
No COVID vaccine	+	1.00
1 dose		0.67 (0.61, 0.74)
2 doses •	10	0.39 (0.36, 0.41)
3 doses	10	0.25 (0.23, 0.26)
4+ doses •		0.41 (0.36, 0.47)
prior SARS-CoV-2	•	0.67 (0.63, 0.72)
Blood cancer	•	1.96 (1.73, 2.22)
Marrow transplant		5 84 (2 41 14 16
Respiratory cancer		1 83 (1 47 2 28)
Padiotherapy in last 6/12		1.80 (1.46 2.45)
Radiotnerapy in last 6/12		2 14 (2 09 4 75)
Solid organ transplant		3.14 (2.00, 4.75)
Immunosuppressants		2.20 (1.92, 2.00)
Leukotriene/LABA	11	1.43 (1.33, 1.54)
Oral steroids	•	2.32 (2.13, 2.53)
COPD	1	1.60 (1.46, 1.76)
Pulm hypertension/fibrosis		1.80 (1.37, 2.35)
Coronary heart disease	•	1.24 (1.14, 1.35)
Stroke		1.27 (1.16, 1.39)
Atrial fibrillation		1.19 (1.08, 1.30)
Congestive cardiac failure		1.31 (1.18, 1.47)
Thromboembolism		1.50 (1.38, 1.63)
PVD	•	1.34 (1.14, 1.57)
Dementia	4	0.95 (0.87, 1.05)
Parkinson's disease		1.80 (1.41, 2.29)
Epilepsy		1.54 (1.36, 1.75)
Rare neuro conditions	•	5 92 (5 22, 6 70)
Osteoporotic fracture		1.12 (1.04 1.20)
Rheumatoid arthritis or SLE		1.54 (1.43, 1.66)
Cirrhoeie of the liver		2 40 (1 97 2 02)
Schizophronia or bisolar		1 53 (1 24 4 74)
Schizophrenia or bipolar		1.03 (1.34, 1.74)
initianimatory bowel disease		1.75 (1.54, 2.00)
SICKIE CEIL OF HIV/AIDS/SCID	•	3.16 (2.59, 3.85)
Type1 diabetes	•	2.66 (2.25, 3.14)
Type2 diabetes		1.51 (1.41, 1.61)
12 25 5	1 2 4 8 16 3	2

(b)

preció tutyD

27

Risk of death due to COVID-19 in at-risk populations (Figure created using data from QCOVID and ISARIC studies).

	Data Source	Sex*		Adjusted HR
Risk: not included				(95% CI)
Age <50	ISARIC		+	Age ref
Age 50-59			_ _	2.63 (2.06-3.35)
Age 60-69				4.99 (3.99-6.25)
Age 70-79				8.51 (6.85-10.57
Age >80				11.09 (8.93-13.77
Obesitv	ISARIC			1.33 (1.19-1.49)
Current smoker	ISARIC			1.09 (0.95-1.26)
Former smoker			-	1.35 (1.26-1.45)
Hypertension	QCOVID4	Male		0.82 (0.45-1.50)
, portonoion	0001101	Female		1.67 (1.12-2.50)
Risk: included		T emaie		1.07 (1.12 2.00)
Non. Included				
COPD	QCOVID4	Male		1 48 (1 28-1 71)
	0001104	Female	_	1.32 (1.20-1.46)
		remaie	_	1.52 (1.20-1.40)
		Mala		1.32 (1.35-1.73)
CHD	QCOVID4	Famala		1.17 (1.05-1.29)
	0.001/100	Female		1.14 (1.01-1.28)
	QCOVID3			1.18 (1.07-1.32)
/ascular disease	QCOVID4	Male		1.07 (0.90-1.28)
		Female		1.51 (1.23-1.86)
	QCOVID3			1.31 (1.09-1.57)
CKD (stage 3)	QCOVID4	Male		1.14 (1.02-1.27)
		Female		1.20 (1.08-1.34)
	QCOVID3			1.23 (1.12-1.36)
Cirrhosis	QCOVID4	Male		2.52 (1.83-3.45)
		Female		1.75 (1.17-2.62)
	QCOVID3			2.96 (2.02-4.34)
Dementia	QCOVID4	Male	-	1.62 (1.45-1.81)
		Female		1.27 (1.14-1.42)
	QCOVID3		-	2.23 (1.98-2.50)
Epilepsy	QCOVID4	Male		1.28 (0.99-1.65)
		Female	_	1.41 (1.07-1.87)
	QCOVID3		_	1.13 (0.85-1.50)
Diabetes (II)	QCOVID4	Male		1.44 (1.30, 1.60)
		Female		1.45 (1.29, 1.62)
	QCOVID3			1.26 (1.12-1.42)
Learning disability	QCOVID4	Male		1.54 (1.19, 2.00)
		Female		1 06 (0 77 1 45)
Mental illness	QCOVID4	Male		1.55 (1.14. 2.11)
neritar innooo	000104	Female		0.91 (0.64, 1.20)
		i emaie		1 12 (0 77,1 62)
	000003		-	1.12 (0.11-1.03)

Sources:

https://www.ons.gov.uk/peoplepopulati onandcommunity/populationandmigrat ion/populationestimates/datasets/pop ulationestimatesforukenglandandwale sscotlandandnorthernireland

MYE1: Popula	tion estima	ates: Sumn	nary for the	e UK, mid-	2021			
This worksheet cor	ntains one table	9.	-					
Please choose from	m the links pres	sented in the ce	ells below to e-	mail us your o	pinion on this ta	able:		
This met my needs	, please produ	ce it next year						
I need something s	lightly different	(please specif	fy)					
This is not what I ne	eed at all (pleas	se specify)						
	United	Great	England				Northern	
Groups/codes	Kingdom	Britain	and Wales	England	Wales	Scotland	Ireland	
Country Code	K02000001	K0300001	K04000001	E92000001	W9200004	S9200003	N9200002	
All Persons	67,026,292	65,121,729	59,641,829	56,536,419	3,105,410	5,479,900	1,904,563	
Females	34,214,835	33,247,086	30,439,748	28,854,074	1,585,674	2,807,338	967,749	
Males	32,811,457	31,874,643	29,202,081	27,682,345	1,519,736	2,672,562	936,814	
Age Groups	No data	No data	No data	No data	No data	No data	No data	
0 to 4	3,580,269	3,467,237	3,211,800	3,058,217	153,583	255,437	113,032	
5 to 9	3,933,947	3,809,411	3,515,684	3,340,262	175,422	293,727	124,536	
10 to 14	4,034,833	3,907,703	3,603,137	3,419,970	183,167	304,566	127,130	
15 to 19	3,794,214	3,680,436	3,396,806	3,222,056	174,750	283,630	113,778	
20 to 24	4,034,799	3,924,493	3,592,515	3,407,413	185,102	331,978	110,306	
25 to 29	4,367,126	4,251,185	3,880,467	3,694,908	185,559	370,718	115,941	
30 to 34	4,655,236	4,529,805	4,146,472	3,950,366	196,106	383,333	125,431	
35 to 39	4,477,368	4,349,739	3,989,765	3,802,908	186,857	359,974	127,629	
40 to 44	4,226,466	4,103,925	3,771,374	3,595,148	176,226	332,551	122,541	
45 to 49	4,214,569	4,093,631	3,755,333	3,571,818	183,515	338,298	120,938	
50 to 54	4,640,482	4,509,869	4,120,078	3,904,317	215,761	389,791	130,613	
55 to 59	4,573,856	4,444,320	4,042,910	3,819,992	222,918	401,410	129,536	
60 to 64	3,956,096	3,842,169	3,481,543	3,280,891	200,652	360,626	113,927	
65 to 69	3,354,034	3,260,087	2,954,663	2,776,651	178,012	305,424	93,947	
70 to 74	3,345,116	3,261,381	2,971,227	2,790,122	181,105	290,154	83,735	
75 to 79	2,490,287	2,423,025	2,218,726	2,084,906	133,820	204,299	67,262	
80 to 84	1,698,442	1,654,382	1,511,707	1,422,689	89,018	142,675	44,060	
85 to 89	1,050,295	1,023,973	937,985	884,349	53,636	85,988	26,322	
90 and over	598,857	584,958	539,637	509,436	30,201	45,321	13,899	
			70+ total	7,691,502				

70-74 booster dose uptake rate March 2023 = 90.2%

Vaccination uptake, by vaccination date age demographics

Total percentage of people who have received a COVID-19 vaccination, by age group. For English areas, the denominator is the number of people aged 12 and over on the National Immunisation Management Service (NIMS) database. For Scottish areas, the denominator is the mid-2020 population estimate for those aged 12 and over. This means comparisons between local areas in different nations should be made with caution. England local area uptake is also not comparable to England national uptake by report date as that uses a different denominator - see the About tab for more information.

Second dose O First dose

Booster or third dose



all 1y 6m 3m 1m									
									o Q 🛞
90+									
85 to 89									
80 to 84									Percentage
75 to 79							Age demogra	phics Date: 11 Mar 2	2023 uptake
70 to 74								Age group: 70 to	o 74
65 to 69								Percentage uptake: 90	0.2%
60 to 64									- 75
55 to 59									
50 to 54									
45 to 49									- 50
40 to 44									
35 to 39									
30 to 34									-25
25 01 29									
16 to 17									
12 to 15									
5 to 11									
51011	I	I	I	I	I.	I.	I.	I	
1 Jan 2021	1 Apr 2021	1 Jul 2021	1 Oct 2021	1 Jan 2022	1 Apr 2022	1 Jul 2022	1 Oct 2022	1 Jan 2023	
A. Download	Share								

Source: https://coronavirus.data.gov.uk/details/vaccinations?areaType=nation&areaName=England

NICE National Institute for Health and Care Excellence

Thank you.

© NICE [insert year]. All rights reserved. Subject to Notice of rights.